Back

Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: predicting adverse effects and prognosis Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Moaad Slieman

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

9 More presentations in this session

Presentation thumbnail
Adverse Myocardial and vascular side effects of Immune Checkpoint Inhibitors: a prospective multimodal cardiovascular assessment (AMICI study)
Doctor M. Mirabel (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes in acute coronary syndrome patients with cancer: a statewide population-linkage study
Doctor C. Yu (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
The CTOX-Score, a clinical risk prediction tool for cardiovascular toxicity secondary to cancer therapies
Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Fibroblast activation in cardio-oncology
Doctor K. Loganath (Southampton, GB)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose co-transporter-2 inhibitors : a potential cardioprotective agent?
Doctor T. Georgopoulou (Heraklion, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology: predicting adverse effects and prognosis

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Cardiovascular disease and its association with outcomes in cancer patients treated with immune checkpoint inhibitors
thumbnail
Congress Presentation
Cardiovascular risks of PD1 inhibitor therapy in cancer: impact of prior ischemic events on heart failure - a retrospective cohort study
thumbnail
Congress Presentation
Heart failure hospitalization and outcomes in cancer patients undergoing immune checkpoint inhibitor treatment: a systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources